Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 460 (ZNF460) is a member of the KRAB-domain containing C2H2-type zinc finger transcription factors. It binds DNA in a sequence-specific manner, potentially regulating gene expression by functioning as a transcriptional regulator. It is encoded on human chromosome 19 and is ubiquitously expressed at low levels in most tissues. ZNF460 has been implicated in the promotion of epithelial–mesenchymal transition (EMT) and cancer metastasis in gastric cancer by transactivating the APOC1 gene; it also drives cancer progression in oral squamous cell carcinoma and supports leukemic cell proliferation in acute myeloid leukemia through the NF-κB pathway. There are currently no known drugs directly targeting this transcription factor, and it is not considered a classical therapeutic target such as a receptor, enzyme, or ion channel; rather, it is a transcription factor with disease association through regulation of cancer-related genes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 460 (ZNF460).